研究单位：[1]Hoffmann-La Roche[2]Beijing Cancer Hospital,Beijing,China,100142[3]Sichuan Cancer Hospital,Chengdu City,China,610041[4]West China Hospital, Sichuan University[5]Department of Breast,Chengdu,China,610041[6]The Second Affiliated Hospital, Chongqing Medical University,Chongqing,China,400010[7]Fujian Medical University Union Hospital,Fuzhou City,China,350001[8]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China,510120[9]The First Affiliated Hospital of College of Medicine, Zhejiang University,Hangzhou,China,310003[10]Qingdao Central Hospital,Qingdao City,China,266042[11]Shanghai Chest Hospital,Shanghai,China,200000[12]Shanghai Pulmonary Hospital,Shanghai,China,200433[13]Tianjin Cancer Hospital,Tianjin,China,300060[14]Henan Cancer Hospital,Zhengzhou,China,450008
研究目的：
This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.
